The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XIII.a

Lung cancer

There is substantial evidence that lung cancer is one longterm complication of alkylating agents used in the treatment of lymphomas including Hodgkin's disease. Abstinence from smoking in this setting is crucially important

Publications

Sapalidis K, Laskou S, Amaniti A, Mantalovas S, Giannakidis D, Koulouris C, Karapantzos I, Karapantzou C, Mponiou K, Tsiouda T, Konstantinou F, Kougioumtzi I, Katsikogiannis N, Sardeli C, Gogakos A, Schizas N, Domeyer P, Zarogoulidis P, Kesisoglou I

Lung cancer induced from chemotherapy a 20 years old case.

Respiratory medicine case reports. 2018;24:32-34

Bluhm EC, Ronckers C, Hayashi RJ, Neglia JP, Mertens AC, Stovall M, Meadows AT, Mitby PA, Whitton JA, Hammond S, Barker JD, Donaldson SS, Robison LL, Inskip PD

Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study.

Blood. 2008;111(8):4014-21

Lorigan P, Radford J, Howell A, Thatcher N

Lung cancer after treatment for Hodgkin's lymphoma: a systematic review.

The Lancet. Oncology. 2005;6(10):773-9

Travis LB, Gilbert E

Lung cancer after Hodgkin lymphoma: the roles of chemotherapy, radiotherapy and tobacco use.

Radiation research. 2005;163(6):695-6

Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, Joensuu T, Lynch CF, van Leeuwen FE, Holowaty E, Storm H, Glimelius I, Pukkala E, Stovall M, Fraumeni JF Jr, Boice JD Jr, Gilbert E

Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease.

Journal of the National Cancer Institute. 2002;94(3):182-92

Hancock SL, Hoppe RT, Horning SJ, Rosenberg SA

Intercurrent death after Hodgkin disease therapy in radiotherapy and adjuvant MOPP trials.

Annals of internal medicine. 1988;109(3):183-9

Horning SJ, Ang PT, Hoppe RT, Rosenberg SA

The Stanford experience with combined procarbazine, Alkeran and vinblastine (PAVe) and radiotherapy for locally extensive and advanced stage Hodgkin's disease.

Annals of oncology : official journal of the European Society for Medical Oncology. 1992;3(9):747-54